TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04407715

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater
Description: The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater
Description: The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
Study: NCT04251494

Intervention type: OTHER
Intervention: Routine blood samples
Description: Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
Study: NCT03567187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera
Description: The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
Study: NCT02834130

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation of psychological and psychopathological
Study: NCT02844855

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive tests
Description: MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tests
Description: MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
Study: NCT03390660

Intervention type: OTHER
Intervention: WIC program participation
Description: WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
Study: NCT06544590

Intervention type: DEVICE
Intervention: taVNS
Description: TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).

Intervention type: DEVICE
Intervention: taVNS
Description: TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).
Study: NCT02844855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tests
Description: MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
Study: NCT02510807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
Study: NCT01485874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil (Pegylated Liposomal Doxorubicin)
Description: Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle
Study: NCT00310310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Apnea Self-Management Program
Description: Sleep apnea self-management program - 4 sessions, group-based.
Study: NCT06544590

Intervention type: DRUG
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Study: NCT00310310

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual sleep apnea and cpap care
Study: NCT01021007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine
Description: Rinse 2 times per day for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Use 2 times per day for 6 weeks
Study: NCT00870688

Intervention type: DRUG
Intervention: sodium valproate
Description: valproate sustained release minitablets, once daily.
Study: NCT06544590

Intervention type: DRUG
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.

Intervention type: DRUG
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Study: NCT03619213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablets given once daily, per oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg
Study: NCT04106388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Behavioral Health Integration
Description: The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
Study: NCT04337437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab
Description: 150 mg/1ml/bottle, single subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for this trial
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
Study: NCT04463706

Intervention type: OTHER
Intervention: Predictors adverse evolution
Description: Predictors adverse evolution in all hospital participant admitted patients

Intervention type: OTHER
Intervention: Predictors of health care provide
Description: Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
Study: NCT04561453

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Description: All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
Study: NCT00893620

Intervention type: DEVICE
Group type: OTHER
Intervention: Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft
Description: These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
Study: NCT01449643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold
Study: NCT04755556

Intervention type: OTHER
Group type: OTHER
Intervention: home based intensive bimanual training
Description: Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy
Description: Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
Study: NCT02411955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.1%
Description: Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac®
Description: Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
Study: NCT01206569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting tacrolimus (Advagraf, Astellas Pharma)
Description: Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
Study: NCT03985176

Intervention type: DEVICE
Intervention: ROTEM
Description: ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH

Intervention type: PROCEDURE
Intervention: EEG
Description: Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH

Intervention type: PROCEDURE
Intervention: bilateral compression ultrasound of the lower extremity veins
Description: to exclude asymptomatic deep venous thrombosis once over days 3 to 7
Study: NCT00619463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
Study: NCT04795349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted breast biopsy
Description: In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
Study: NCT00218959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos \& Monelli).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Study: NCT01225341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: onabotulinumtoxinA
Description: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study: NCT00104689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02344732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homatropine 2% eye drops thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Study: NCT01225341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic normal saline
Description: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacteriostatic normal saline
Description: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study: NCT04271267

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT01830530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two tablets daily in the morning
Study: NCT01994083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01
Description: Administered orally
Study: NCT02386774

Intervention type: DEVICE
Group type: OTHER
Intervention: Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
Description: used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml

Intervention type: DEVICE
Group type: OTHER
Intervention: Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)
Description: used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine
Study: NCT01383486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium ER (BAYH6689)
Description: Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advil
Description: Commercially available Advil; oral caplet upon incidence of pain
Study: NCT03666728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200 mg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: BP102 was administered 15 mg/kg iv every 3 weeks
Study: NCT03592953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game simulation training sessions
Description: Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game simulation training sessions
Description: Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios.
Study: NCT04414891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).
Study: NCT06416826

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibroacoustic Therapy System - VTS 1000
Description: Participants will undertake 15 self-administered sessions of RSS 40Hz low frequency sound stimulation, 30 minutes daily, over 3 weeks (5 days/week).
Study: NCT04277390

Intervention type: OTHER
Intervention: clinical intervention for microbial analysis and MIR155 as biomarker
Description: Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated

Intervention type: OTHER
Intervention: clinical intervention for microbial analysis and MIR155 as biomarker
Description: Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated

Intervention type: OTHER
Intervention: clinical intervention for microbial analysis and MIR155 as biomarker
Description: Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated

Intervention type: OTHER
Intervention: clinical intervention for microbial analysis and MIR155 as biomarker
Description: Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
Study: NCT01449643

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Threshold
Study: NCT03347578

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
Study: NCT02125604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: capsules administered according to the prevailing product label
Study: NCT03133962

Intervention type: OTHER
Group type: OTHER
Intervention: Adult patients who are candidates for a CAP or long-term central catheter placement
Description: Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
Study: NCT03171428

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Surgery for liver tumors is the removal of a part of the liver affected by a tumor.

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
Study: NCT02324127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hsp90
Description: Detect plasma Hsp90α concentration of lung cancer patients
Study: NCT02364401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Catheter ablation for atrial fibrillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Catheter ablation for atrial fibrillation
Study: NCT01514786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Web
Description: The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
Study: NCT03276520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ethyl glucuronide
Description: alcohol urine screening with ethyl glucuronide

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: alcohol urine screening with ethanol
Study: NCT00434239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Ancestim
Description: Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
Study: NCT04118452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based early childhood developmental care coordination
Description: The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.